PhRMA Statement on Decision of the European General Court on EMA Disclosure of Company Data

WASHINGTON, D.C. (April 30, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matt Bennett issued the following statement today:

Nearly 200 Medicines in Development for Mental Illnesses

Washington, D.C. (July 12, 2012) — America’s biopharmaceutical research companies are developing 187 innovative medicines to help the nearly 60 million patients in the United States who are suffering from some form of mental illness.

Research in Maine

America’s Biopharmaceutical Companies’ Commitment to Research Remains Strong Despite Challenges

Washington, D.C. (April 11, 2013) — Investment in research and development (R&D) by member companies of the Pharmaceutical Research and Manufacturers of America (PhRMA) remained strong at an estimated $48.5 billion in 2012, despite economic, scientific, and business challenges. These efforts are highlighted in PhRMA’s 2013 Biopharmaceutical Research Industry Profile released today.

Biopharmaceuticals in Perspective: Chart Pack 2013

Older American Backgrounder

Medicines in Development for Women Backgrounder

Breast cancer affected an estimated 207,090 American women and killed 39,840 in 2010, according to the American Cancer Society.

Vaccines in Development

Alzheimer’s Disease – An immunotherapeutic amyloid-beta (Aß) peptide conjugate vaccine is in development for the treatment of Alzheimer’s disease. The vaccine therapy stimulates the body to produce antibodies to amyloid-beta protein and remove it from the brain.

Rare Diseases FAQ

How can you find out about clinical research on rare diseases?

Medicines in Development for Older Americans - Report Overview


Subscribe to RSS - Innovation